Literature DB >> 6200949

Selective determination of alpha 2-plasmin inhibitor activity in plasma using chromogenic substrate.

T Matsuda, M Ogawara, R Miura, T Seki, T Matsumoto, Y Teramura, K Nakamura.   

Abstract

In determination of antiplasmin activity of alpha 2-plasmin inhibitor (alpha 2 PI) using an amidolytic method, alpha 2-macroglobulin (alpha 2 M) in concentrations present in normal plasma inhibits the cleavage of chromogenic substrates by plasmin even if the reaction time between alpha 2M and plasmin is shortened as much as possible. The purpose of this study was to develop a new method to assay alpha 2 PI selectively with the chromogenic substrate S-2251 using an end-point method. The antiplasmin activity of alpha 2 M was destroyed by the addition of methylamine hydrochloride. In a case of congenital alpha 2 PI deficiency, antiplasmin activity determined with the previous method without the addition of methylamine was 20% of normal plasma, whereas the results obtained using this newly developed method was 5%. A statistically significant correlation between alpha 2 PI levels determined with this method and with a single radial immunodiffusion method was observed in plasma samples collected from 40 healthy subjects and 11 patients with disseminated intravascular coagulation (DIC). In two cases of DIC, in which markedly depleted levels of alpha 2 PI and normal concentrations of alpha 2 M were observed, antiplasmin activities measured without the addition of methylamine were higher than the ones measured immunologically, whereas the results obtained with the method described here were in accordance with the antigenicities of alpha 2 PI.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6200949     DOI: 10.1016/0049-3848(84)90077-x

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  4 in total

1.  Proteomics of specific treatment-related alterations in Fabry disease: a strategy to identify biological abnormalities.

Authors:  David F Moore; Oleg V Krokhin; Ronald C Beavis; Markus Ries; Chevalia Robinson; Ehud Goldin; Roscoe O Brady; John A Wilkins; Raphael Schiffmann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-14       Impact factor: 11.205

Review 2.  Molecular Mechanisms and Therapeutics for the GAA·TTC Expansion Disease Friedreich Ataxia.

Authors:  Joel M Gottesfeld
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

3.  Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and α2-Antiplasmin Inactivation.

Authors:  Satish Singh; Aiilyan Houng; Guy L Reed
Journal:  Circulation       Date:  2016-12-27       Impact factor: 29.690

4.  Criteria for the Specific Measurement of Plasmin Inhibitor Activity Using an Enzymatic Procedure.

Authors:  Piet Meijer; Michel Hanss; Ulla Christensen; Bjorn Wiman; Kees Kluft
Journal:  EJIFCC       Date:  2001-07-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.